ReviewMolecular biology reports2026
The role of Junctional Adhesion Molecule-A (JAM-A) in breast cancer metastasis.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Junctional Adhesion Molecule A (JAM-A) is a multifunctional cell surface protein, belonging to the immunoglobulin superfamily of cell adhesion receptors involved in tight-junction formation. The molecule regulates breast cancer growth and invasion, and influences intercellular interactions between leukocytes, platelets and endothelial or epithelial cells, which influence metastatic progression. The main aim of this review is to provide an overview of the functional role of JAM-A in breast cancer metastasis, including its molecular interactions, cellular functions and contribution to inter alia cell migration, cell adhesion, epithelial-to-mesenchymal transition, apoptosis and metastasis. However, the molecular mechanism and signaling pathways regulating JAM-A protein in breast cancer are still not fully defined and require further investigation. Nevertheless, JAM-A appears a promising target for future diagnostic applications and drug development in breast cancer.
Indexed as
Identifiers
41824099What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.